![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/sapience-therapeutics-presents-positive-clinical-and-biomarker-data-from-st101-phase-2-study-in-gbm-at-asco-2024-in-oral-presentation-302161146.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-to-showcase-clinical-and-biomarker-data-from-st101-phase-2-study-in-gbm-at-asco-2024-302154660.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-presents-three-posters-at-the-american-association-for-cancer-research-aacr-annual-meeting-2024-302110096.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-to-present-multiple-posters-at-the-american-association-for-cancer-research-aacr-annual-meeting-2024-302080292.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-presents-st101-clinical-data-and-st316-preclinical-data-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-301956237.html
https://www.clinicaltrialsarena.com/news/sapience-st316-solid-tumours/
https://www.prnewswire.com/news-releases/sapience-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-study-of-its-first-in-class--catenin-antagonist-st316-in-advanced-solid-tumors-301849508.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-to-present-late-breaking-data-on-st101-and-st316-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023-301797273.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-announces-late-breaking-research-poster-presentations-on-st101-and-st316-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023-301773763.html
https://www.prnewswire.com/news-releases/sapience-therapeutics-receives-ind-clearance-from-fda-to-proceed-with-phase-1-2-study-of-st316-in-patients-with-solid-tumors-301771021.html